gefitinib has been researched along with Bile Duct Neoplasms in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoudjehane, L; Clapéron, A; Conti, F; Desbois-Mouthon, C; Firrincieli, D; Fouassier, L; Ho-Bouldoires, TH; Housset, C; Merabtene, F; Mergey, M; Prignon, A; Scatton, O; Wendum, D | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Chang, VH; Chen, CC; Jiang, X; Lin, HY; Liu, YR; Wang, J; Yang, SH; Yen, Y; Zhang, K | 1 |
| Egawa, S; Katayose, Y; Mizuma, M; Motoi, F; Oda, A; Ohtuska, H; Oikawa, M; Onogawa, T; Rikiyama, T; Sasaki, T; Shirasou, S; Unno, M; Yabuuchi, S; Yamamoto, K; Yoshida, H | 1 |
| Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H | 1 |
| Bronk, SF; Gores, GJ; Gwak, GY; Lee, HS; Werneburg, NW; Yoon, JH | 1 |
| Chayama, K; Kuwahara, K; Miyata, H; Sasaki, T; Serikawa, M | 1 |
| Altiok, S; Amador, ML; Chan, A; Hidalgo, M; Jimeno, A; Maitra, A; Mezzadra, H; Nielsen, ME; Patel, P | 1 |
1 review(s) available for gefitinib and Bile Duct Neoplasms
| Article | Year |
|---|---|
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
7 other study(ies) available for gefitinib and Bile Duct Neoplasms
| Article | Year |
|---|---|
Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Disease Progression; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Mice; Myofibroblasts; Quinazolines; Signal Transduction; Stromal Cells | 2013 |
Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Protein Serine-Threonine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2015 |
ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Cycle; Cell Proliferation; Cholangiocarcinoma; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Quinazolines; Radiation Tolerance; Tumor Cells, Cultured; X-Rays | 2009 |
Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Cyclooxygenase 2; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Membrane Proteins; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Quinazolines; Signal Transduction; Tyrphostins; Ubiquitin | 2004 |
The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines.
Topics: Anthracenes; Bile Duct Neoplasms; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Clone Cells; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Morpholines; Nitriles; Oncogene Protein v-akt; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Quinazolines; Radiation-Sensitizing Agents | 2006 |
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
Topics: Animals; Antineoplastic Agents; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy, Fine-Needle; Cholangiocarcinoma; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Signal Transduction | 2006 |